The spectacular enchancment of total survival in a number of myeloma (MM) sufferers within the final years has been largely associated to the supply of latest lessons of medicine with totally different mechanisms of motion, together with proteasome inhibitors (PI), immunomodulating brokers (IMiDs), and monoclonal antibodies. Nevertheless, even with this elevated potence of fireplace, MM nonetheless stays an incurable situation, as a consequence of clonal choice and evolution of neoplastic clone. This idea underlines the significance of immunotherapy as one of the crucial related instruments to attempt to eradicate the illness.
In keeping with this idea, energetic and passive immunotherapies characterize essentially the most enticing strategy to this intention. Antibody-drug conjugate(s) (ADCs) and bispecific antibodies (BsAbs) embody two progressive instruments in an effort to restrict neoplastic plasma cell development and even, if used on the time of one of the best response, to doubtlessly eradicate the tumoral clone. Following their promising outcomes as single agent for superior illness, on the latest 62nd ASH assembly, encouraging knowledge of a number of combos, notably of ADC(s) with PI or IMiDs, have been reported, suggesting even higher outcomes for sufferers handled earlier. On this paper, we reviewed the traits, mechanism of motion, and scientific knowledge accessible for many related ADC(s) and BsAbs.
Interspecies Scaling of Antibody-Drug Conjugates (ADC) for the Prediction of Human Clearance
Allometric scaling is a useful gizmo for the extrapolation of pharmacokinetic parameters from animals to people. The target of this research was to foretell human clearance of antibody-drug conjugates (ADC) allometrically from one to a few animal species and evaluate the anticipated human clearance with the noticed human clearance. For 3 animal species allometric scaling, the “Rule of Exponents” (ROE) was used. The outcomes of the research indicated that three-species allometric scaling in affiliation with the ROE supplies acceptable prediction (inside 0.5-2-fold prediction error) of human clearance.
The 2-species allometric scaling resulted in substantial prediction error. One-species scaling utilizing a hard and fast exponent of 1.Zero offered acceptable prediction error (inside 0.5-2-fold) by monkey, rat, and mouse, through which monkey and rat have been comparable. General, the anticipated human clearance values of ADCs from animal(s) was good. The allometric methodology proposed on this article can be utilized to foretell human clearance from the animal knowledge and subsequently to pick the first-in-human dose of ADCs.
Expeditious Era of Biparatopic Widespread Gentle Chain Antibodies through Rooster Immunization and Yeast Show Screening
Bispecific (BsAb) and biparatopic (BpAb) antibodies emerged as promising codecs for therapeutic biologics exhibiting tailored purposeful properties. Over latest years, chicken-derived antibodies have gained traction for diagnostic and therapeutic functions as a consequence of their broad epitope protection and comfort of library era. Right here we report the primary era of a biparatopic frequent gentle chain (cLC) chicken-derived antibody by an epitope binning-based screening strategy utilizing yeast floor show.

The ensuing monospecific antibodies goal conformational epitopes on area II or III of the epidermal development issue receptor (EGFR) with decrease double- or single-digit nanomolar affinities, respectively. Moreover, the area III concentrating on variant was proven to intrude with epidermal development issue (EGF) binding. Using the Knob-into-Gap expertise (KiH), a biparatopic antibody with subnanomolar affinity was generated that facilitates clustering of soluble and cell-bound EGFR and displayed enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) in comparison with the parental antibodies. This technique for producing cLC-based biparatopic antibodies from immunized chickens might pave the way in which for his or her additional improvement in therapeutic settings.
Glycoengineering of AAV-delivered monoclonal antibodies yields elevated ADCC exercise
The absence of fucose on asparagine-297 of the human immunoglobulin G (IgG) heavy chain has been proven to reinforce antibody-dependent mobile cytotoxicity (ADCC) exercise by 10- to 100-fold in comparison with fucosylated antibody. Our lab is learning using adeno-associated virus (AAV) as a vector for the supply of HIV-specific antibodies for therapeutic functions. For the reason that antibody is produced by vector-transduced cells in vivo, present methods of glycoengineering can’t be utilized. As a way to obtain comparable enhancement of ADCC with AAV-delivered antibodies, brief hairpin RNAs (shRNAs) that focus on fucosyltransferase-8 (FUT8), have been designed, examined, and cloned into AAV vectors used to ship HIV-specific broadly neutralizing antibodies (bNAbs).
Antibodies produced by our glycoengineered-AAV (GE-AAV) vectors have been analyzed for fucose content material and ADCC. GE-AAV constructs have been capable of obtain over 80% knockdown of FUT8. Outcomes have been confirmed by lectin western blot for α1-6 fucose, which revealed virtually an entire absence of fucose on GE-AAV-produced antibodies. GE-AAV-produced antibodies revealed >10-fold enhancement of ADCC, whereas exhibiting similar neutralization and gp140 trimer binding in comparison with their fucosylated counterparts.
IL-1 R2 (Human) Sandwich ELISA Kit |
|
OK-0229 |
Assay Biotech |
1Kit |
EUR 280 |
|
Description: IL-1 R2 (Human) Colorimetric Sandwich ELISA Kit |
IL-1 R2 (Human) OmniKine ELISA Kit |
|
MBS9501955-1x96Wells |
MyBiosource |
1x96Wells |
EUR 500 |
IL-1 R2 (Human) OmniKine ELISA Kit |
|
MBS9501955-5x96Wells |
MyBiosource |
5x96Wells |
EUR 2300 |
IL-1 R2 ELISA Kit (Human) : 96 Wells (OKAG00129) |
|
OKAG00129 |
Aviva Systems Biology |
96 Wells |
EUR 715.2 |
|
Description: Description of target: The protein encoded by this gene is a cytokine receptor that belongs to the interleukin 1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type I(IL1R1/IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. Interleukin 4 (IL4) is reported to antagonize the activity of interleukin 1 by inducing the expression and release of this cytokine. This gene and three other genes form a cytokine receptor gene cluster on chromosome 2q12. Alternative splicing results in multiple transcript variants and protein isoforms. Alternative splicing produces both membrane-bound and soluble proteins. A soluble protein is also produced by proteolytic cleavage.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 32 pg/mL |
IL 1 R2 Recombinant Protein |
|
96-436 |
ProSci |
0.1 mg |
EUR 619.8 |
|
Description: Interleukin-1 receptor type 2 (IL1R2) is also known as CD121 antigen-like family member B (CDw121b), IL-1 type II receptor, Interleukin-1 receptor type II, belongs to the interleukin-1 receptor family. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). IL1R2 is non-signaling receptor for IL1A, IL1B and IL1RN, reduces IL1B activities. Serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. IL1R2 modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors. |
Mouse Anti Human IL-1 beta |
|
MBS140161-05mg |
MyBiosource |
0.5mg |
EUR 440 |
Mouse Anti Human IL-1 beta |
|
MBS140161-1mg |
MyBiosource |
1mg |
EUR 600 |
Mouse Anti Human IL-1 beta |
|
MBS140161-5x1mg |
MyBiosource |
5x1mg |
EUR 2375 |
Recombinant Mouse IL-1 R2/IL-1 RII Protein |
|
RP00726 |
Abclonal |
10μg |
EUR 138.16 |
|
|
Recombinant Mouse IL-1 R2/IL-1 RII Protein |
|
RP00729 |
Abclonal |
10μg |
EUR 138.16 |
Anti‐Human IL‐17A |
|
E2790213 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Mouse Anti Human IL-1 beta FITC |
|
MBS140163-05mg |
MyBiosource |
0.5mg |
EUR 440 |
Mouse Anti Human IL-1 beta FITC |
|
MBS140163-1mg |
MyBiosource |
1mg |
EUR 600 |
Mouse Anti Human IL-1 beta FITC |
|
MBS140163-5x1mg |
MyBiosource |
5x1mg |
EUR 2375 |
human anti-human IL-1 β mAb(14) |
|
E4A09D02-14 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human IL-1 β mAb(7Z) |
|
E4A09D02-7Z |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Monoclonal Mouse anti Human IL-1 beta |
|
MBS550073-05mg |
MyBiosource |
0.5mg |
EUR 595 |
Monoclonal Mouse anti Human IL-1 beta |
|
MBS550073-1mg |
MyBiosource |
1mg |
EUR 915 |
Mouse Anti Human IL-1 beta Biotinylated |
|
MBS140162-05mg |
MyBiosource |
0.5mg |
EUR 440 |
Mouse Anti Human IL-1 beta Biotinylated |
|
MBS140162-1mg |
MyBiosource |
1mg |
EUR 600 |
Mouse Anti Human IL-1 beta Biotinylated |
|
MBS140162-5x1mg |
MyBiosource |
5x1mg |
EUR 2375 |
anti-PKA R2 |
|
YF-PA24454 |
Abfrontier |
50 ul |
EUR 400.8 |
|
Description: Mouse polyclonal to PKA R2 |
anti-PKA R2 |
|
YF-PA13990 |
Abfrontier |
50 ul |
EUR 435.6 |
|
Description: Mouse polyclonal to PKA R2 |
human anti-human IL-2 mAb |
|
E409C12-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
human anti-human IL-4 mAb |
|
E409C13-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
human anti-human IL-5 mAb |
|
E409C14-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
human anti-human IL-8 mAb |
|
E409C16-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
human anti-human IL-5 mAb |
|
E4A09D05 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
Human anti-Human IL-2 mAb |
|
MBS8576800-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-2 mAb |
|
MBS8576800-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-2 mAb |
|
MBS8576800-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-2 mAb |
|
MBS8576800-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-2 mAb |
|
MBS8576800-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Human anti-Human IL-4 mAb |
|
MBS8576802-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-4 mAb |
|
MBS8576802-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-4 mAb |
|
MBS8576802-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-4 mAb |
|
MBS8576802-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-4 mAb |
|
MBS8576802-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Human anti-Human IL-5 mAb |
|
MBS8576804-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-5 mAb |
|
MBS8576804-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-5 mAb |
|
MBS8576804-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-5 mAb |
|
MBS8576804-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-5 mAb |
|
MBS8576804-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Human anti-Human IL-8 mAb |
|
MBS8576808-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-8 mAb |
|
MBS8576808-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-8 mAb |
|
MBS8576808-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-8 mAb |
|
MBS8576808-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-8 mAb |
|
MBS8576808-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
human anti-human IL-1β mAb |
|
E409C11-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
human anti-human IL-10 mAb |
|
E409C17-h100 |
EnoGene |
100μL |
EUR 395 |
|
Description: Available in various conjugation types. |
Human anti-Human IL-10 mAb |
|
MBS8576810-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-10 mAb |
|
MBS8576810-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-10 mAb |
|
MBS8576810-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-10 mAb |
|
MBS8576810-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-10 mAb |
|
MBS8576810-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
human anti-human IL-17A mAb |
|
E409C18-h100 |
EnoGene |
100μL |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
Human anti-Human IL-1beta mAb |
|
MBS8576798-005mg |
MyBiosource |
0.05mg |
EUR 325 |
Human anti-Human IL-1beta mAb |
|
MBS8576798-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human anti-Human IL-1beta mAb |
|
MBS8576798-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human anti-Human IL-1beta mAb |
|
MBS8576798-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human anti-Human IL-1beta mAb |
|
MBS8576798-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
human anti-human IL-12/IL-23 p40 mAb(3H2) |
|
E4A09D33-3H2 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human IL-12/IL-23 p40 mAb(5N9) |
|
E4A09D33-5N9 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human anti-human IL-12/IL-23 p40 mAb (3H2) |
|
A09D33-3H2 |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-12/IL-23 p40 mAb (5N9) |
|
A09D33-5N9 |
BioNC |
1 Each |
Ask for price |
human anti-human IL-12/IL-23 p40 mAb(1G11) |
|
E4A09D33-1G11 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human anti-human IL-12/IL-23 p40 mAb (1G11) |
|
A09D33-1G11 |
BioNC |
1 Each |
Ask for price |
ApoE R2, Recombinant Human |
|
MBS636329-005mg |
MyBiosource |
0.05mg |
EUR 880 |
ApoE R2, Recombinant Human |
|
MBS636329-5x005mg |
MyBiosource |
5x0.05mg |
EUR 3730 |
Anti-Human TGF beta R2 Antibody |
|
101-M178 |
ReliaTech |
100 µg |
EUR 399 |
|
Description: Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70 - 85 kDa), and Type III (250 - 350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta1 and TGF-beta 3 with high affinity and TGF-beta 2 with much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta. The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543245-006mL |
MyBiosource |
0.06mL |
EUR 250 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543245-012mL |
MyBiosource |
0.12mL |
EUR 370 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543245-02mL |
MyBiosource |
0.2mL |
EUR 550 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543246-006mL |
MyBiosource |
0.06mL |
EUR 250 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543246-012mL |
MyBiosource |
0.12mL |
EUR 370 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|
MBS2543246-02mL |
MyBiosource |
0.2mL |
EUR 550 |
Mouse Monoclonal anti-human Orexin R2 |
|
hAP-0850 |
Angio Proteomie |
50ug |
EUR 400 |
MOUSE ANTI HUMAN CD126 (IL-6R) |
|
MBS213171-01mg |
MyBiosource |
0.1mg |
EUR 355 |
MOUSE ANTI HUMAN CD126 (IL-6R) |
|
MBS213171-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1425 |
human anti-human IL-2 mAb(1H) |
|
E409C12-hA100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-2 mAb(2H) |
|
E409C12-hB100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-8 mAb(1H) |
|
E409C16-hA100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-8 mAb(2H) |
|
E409C16-hB100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-2 mAb(D1) |
|
E4A09D03-A7C |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-2 mAb(F5) |
|
E4A09D03-B1F |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-2 mAb(16) |
|
E4A09D03-C3C |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-4 mAb(12) |
|
E4A09D04-12 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-4 mAb(52) |
|
E4A09D04-52 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-4 mAb(C1) |
|
E4A09D04-C1 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-6 mAb(A3) |
|
E4A09D06-hA3 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-8 mAb(1F) |
|
E4A09D07-1F |
EnoGene |
100ug |
EUR 595 |
human anti-human IL-8 mAb(A5) |
|
E4A09D07-A5A |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-8 mAb(6G) |
|
E4A09D07-B5G |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-8 mAb(AB) |
|
E4A09D07-C8A |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-8 mAb(N2) |
|
E4A09D07-N2 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human IL-8 mAb(N8) |
|
E4A09D07-N8 |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human anti-human IL-2 mAb (D1) |
|
A09D03-A7C |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-2 mAb (F5) |
|
A09D03-B1F |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-2 mAb (16) |
|
A09D03-C3C |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-4 mAb (C1) |
|
A09D04-C1 |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (1F) |
|
A09D07-1F |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (A5) |
|
A09D07-A5A |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (6G) |
|
A09D07-B5G |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (AB) |
|
A09D07-C8A |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (N2) |
|
A09D07-N2 |
BioNC |
1 Each |
Ask for price |
Human anti-human IL-8 mAb (N8) |
|
A09D07-N8 |
BioNC |
1 Each |
Ask for price |
human anti-human IL-1β mAb(1H) |
|
E409C11-hA100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-1β mAb(2H) |
|
E409C11-hB100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-10 mAb(1H) |
|
E409C17-hA100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-10 mAb(2H) |
|
E409C17-hB100 |
EnoGene |
Inflammation-Storm-Antibodies |
EUR 276.5 |
|
Description: Inflammation Storm Antibodies |
human anti-human IL-1β mAb(95) |
|
E4A09D02-h9 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-1β mAb(Ca) |
|
E4A09D02-hA |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-1β mAb(Ge) |
|
E4A09D02-hB |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-5 mAb(E10) |
|
E4A09D05-E10 |
EnoGene |
100ug |
EUR 595 |
human anti-human IL-5 mAb(Q12) |
|
E4A09D05-Q12 |
EnoGene |
100ug |
EUR 595 |
human anti-human IL-6 mAb(10C) |
|
E4A09D06-h10C |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-6 mAb(2D2) |
|
E4A09D06-hD2 |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-10 mAb(97) |
|
E4A09D08-A9D |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-10 mAb(18) |
|
E4A09D08-B2G |
EnoGene |
50ug |
EUR 255 |
|
Description: Available in various conjugation types. |
human anti-human IL-15 mAb(1A) |
|
E4A09D21-1A |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human IL-15 mAb(2B) |
|
E4A09D21-2B |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
human anti-human IL-15 mAb(7C) |
|
E4A09D21-7C |
EnoGene |
50ug |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
ADCC was enhanced 40- to 60-fold when mixed with key Fc mutations recognized to reinforce binding to FcγRIIIA. Our findings outline a robust strategy for supercharging AAV-delivered anti-HIV antibodies.